Strona główna
  • Psychiatria - Gałecki
  • PZWL - najlepsze okazje
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
  • Nowy
Sclerotherapy. From Basic Science to Clinical Practice.

Sclerotherapy. From Basic Science to Clinical Practice.

9783032327932
701,00 zł
630,90 zł Zniżka 70,10 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 630,90 zł
Ilość
Od 7 do 14 dni roboczych

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DHL, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis

This book offers a unique opportunity to integrate basic science with clinical expertise for the optimal use of sclerotherapy in the lower limb and pelvic regions. Authored by world-renowned key opinion leaders from across the globe, it combines evidence-based insights with practical guidance, enabling readers to enhance both their theoretical understanding and technical skills.

Drawing on the diverse international backgrounds of its contributors, the book provides a truly global perspective on contemporary sclerotherapy practice. It is enriched with practical tips and tricks derived from the authors’ extensive clinical experience, making it highly relevant for everyday use.

Designed to guide readers from foundational principles to the most advanced techniques, this comprehensive resource will engage vein specialists at every stage of their professional journey. It is particularly valuable in light of the widespread adoption of this essential therapeutic and aesthetic modality.

Szczegóły produktu
Springer Nature
105069
9783032327932

Opis

Miejsce wydania
Berlin
Rok wydania
2026
Numer wydania
1
Oprawa
twarda
Liczba stron
313
Wymiary (mm)
183 x 261
    1. Sclerotherapy
    2. Foreword
    3. Preface
    4. Acknowledgments
    5. Contents
    6. About the Editors
    7. 1. Sclerotherapy: Past, Present, and Future
    8. 1 Historical Background
    9. 2. Venous Patho-physiology Applied to the Sclerotherapy Act
    10. 1 Anatomy and Hemodynamics
    11. 2 Histology
    12. 3 Sclerotherapy Complications in Histological Perspective
    13. 4 Sclerotherapy Agents Basic Science
    14. 5 Integrating Histology and Clinical Decision-Making
    15. 3. Sclerosing Agents
    16. 1 Sclerosing Agents’ Classification
    17. 2 Detergent Sclerosants
    18. 2.1 Polidocanol (Lauromacrogol 400)
    19. 2.2 Sodium Tetradecyl Sulfate (STS)
    20. 2.3 Sodium Morrhuate
    21. 2.4 Ethanolamine Oleate
    22. 3 Osmotic Sclerosants
    23. 3.1 Hypertonic Saline
    24. 3.2 Hyperosmolar Saline-Dextrose Mixtures
    25. 4 Chemical Irritant Sclerosants
    26. 4.1 Chromated Glycerin and Glycerin Solutions
    27. 4.2 Sodium Iodide and Polyiodide Solutions
    28. 4.3 Sodium Salicylate
    29. 4.4 Absolute Ethanol
    30. 4.5 Bleomycin
    31. 4.6 Doxycycline
    32. 5 Safety General Considerations
    33. 6 Regulatory Considerations
    34. 4. Sclerotherapy Foam Production Techniques
    35. 1 Evolution of Foam Sclerotherapy
    36. 2 Foam Hemodynamics and Clinical Features
    37. 3 Fundamental Concepts in Foam Sclerotherapy Production
    38. 4 Foam Quality Determinants
    39. 5 Manual Foam Production Techniques
    40. 6 Considerations on Material and Equipment
    41. 7 Proprietary Microfoam Systems
    42. 8 Integration of Foam Production with Delivery Technique
    43. 9 Foam Volume, Distribution, and Migration Control
    44. 10 Safety Considerations Related to Foam Production
    45. 11 Failures Identification and Related Solution
    46. 12 Emerging Research and Future Directions
    47. 5. Sclerosant Bubbles’ Physics, Biochemistry, and Translational Medicine Properties
    48. 1 Introduction
    49. 1.1 Foundational Safety Principles of Pharmaceutical Microfoam
    50. 1.2 The Concept of Action and Sclerosis
    51. 2 Pharmaceutical Concepts
    52. 2.1 Specific and Nonspecific Drugs
    53. 2.2 Amphipathic Substances: Developing Clinical Intuition
    54. 2.3 Sclerosant–Endothelium Interaction: Endothelial Disruption Driven by Amphipathic Properties
    55. 2.4 Pharmaceutical Concept of Active Surface
    56. 2.5 Design Principles of Therapeutic Pharmaceutical Microfoam
    57. 2.6 Bubble Micronization: Increasing the Active Surface and Enhancing Sclerosing Capacity
    58. 3 Microfoam in the Site of Action
    59. 3.1 Large Vein Sclerosis: From Historical Limitations to Structure-Driven Solutions
    60. 3.2 Viscosity and Mechanical Action
    61. 3.3 Bubble Echogenicity and Ultrasound Visibility
    62. 3.4 Exclusive Vessel Occupation
    63. 4 Intravascular Gas Bubbles Within the Human Circulatory System
    64. 4.1 Systemic Neutralization of Bubbles After Action
    65. 4.2 Gas Composition, Nitrogen, and Intravascular Safety
    66. 4.3 Cerebral Safety, Patent Foramen Ovale, and Regulatory Oversight
    67. 5 Pharmacologic and Physicochemical Properties
    68. 5.1 Structure Delivers Function
    69. 5.2 Stability Factors in Pharmaceutical-Grade Sclerosing Microfoam
    70. 5.3 Encoding Functionality During Foam Synthesis
    71. 5.4 From Structure to Bedside: Clinical Translation
    72. 5.5 From Intuition to Orientation: A Formal Language for Navigating Microfoam
    73. 5.6 Why Clinicians Should Care
    74. 5.7 Structural Synthesis and Control of Foam Trajectories
    75. 5.8 Take-Home Idea
    76. Appendix A—Surface Area, Bubble Number, and Endothelial Contact
    77. A.1 Geometric Premise
    78. A.2 Pharmacological Consequence
    79. A.3 Structural Limitation and Biological Reality
    80. A.4 Transition Toward a Structural Description
    81. Appendix B—HyDeF: A Geometric Language for Foam Structure and Evolution
    82. B.1 Rationale and Conceptual Scope
    83. B.2 Foam as a Structural State
    84. B.3 Hypervector Representation and Configuration Space
    85. B.4 Structural Evolution as Trajectories in Configuration Space
    86. B.5 The Eigenschaum: Uniformity as a Geometric Horizon
    87. B.6 Proximity to the Eigenschaum and the Definition of EPI
    88. B.7 A Canonical Example of Structural Evolution Within HyDeF
    89. B.7.1 Radius and Internal Pressure
    90. B.7.2 Laplace Difference Operator
    91. B.7.3 Adjacency-Filtered Redistribution
    92. B.7.4 Constitutive Transfer Law (Molar Flux)
    93. B.7.5 Volume Update and Trajectory Generation
    94. B.8 Experimental and Clinical Interfaces
    95. B.9 Reading Guide
    96. 6. Foam Science in Clinical Practice
    97. 1 Introduction
    98. 2 Fundamentals of Medical Foam Science
    99. 3 Translation into Everyday Clinical Practice
    100. 4 Intravascular Evolution of Foam after Injection
    101. 5 Safety Considerations Rooted in Foam Science
    102. 6 Foam Sclerotherapy Filters
    103. 7 Clinical Considerations on Foam Half-Life
    104. 8 Stabilizers
    105. 9 Conclusions
    106. 7. Safety Profiles, Indications, and Contraindications
    107. 1 Safety Considerations in Sclerotherapy
    108. 2 Sclerotherapy Clinical Practice Safety Aspects
    109. 3 Foam Specific Safety Considerations
    110. 4 Indications for Sclerotherapy
    111. 5 Contraindications
    112. 6 Venous Thromboembolism Risk
    113. 7 Patient Characteristics Leading to Possible Contraindication
    114. 8 Precautions
    115. 8. Complications of Sclerotherapy
    116. 1 Introduction
    117. 2 Local Complications
    118. 2.1 Post-Sclerotherapy Pigmentation (PSP)
    119. 2.1.1 Incidence
    120. 2.1.2 Pathophysiology
    121. 2.1.3 Diagnosis
    122. 2.1.4 Management
    123. 2.1.5 Prevention
    124. 2.2 Telangiectatic Matting (TM)
    125. 2.2.1 Incidence
    126. 2.2.2 Pathophysiology
    127. 2.2.3 Clinical Presentation
    128. 2.2.4 Management
    129. 2.2.5 Prevention
    130. 2.3 Injection Site Reactions
    131. 2.3.1 Pain, Ecchymosis, and Edema
    132. 2.4 Superficial Venous Thrombosis (SVT)
    133. 2.4.1 Incidence and Pathophysiology
    134. 2.4.2 Diagnosis
    135. 2.4.3 Management
    136. 2.5 Cutaneous Necrosis and Ulceration
    137. 3 Systemic Complications
    138. 3.1 Venous Thromboembolism (VTE)
    139. 3.1.1 Deep Vein Thrombosis (DVT)
    140. 3.1.2 Pulmonary Embolism (PE)
    141. 3.2 Neurological Events
    142. 3.2.1 Migraine and Transient Visual Disturbances
    143. 3.2.2 Transient Ischemic Attack (TIA) and Stroke
    144. 3.3 Allergic Reactions
    145. 3.4 Cardiopulmonary Events
    146. 4 Conclusions
    147. 9. Sclerotherapy for Lower Limb Chronic Venous Disease
    148. 1 Chronic Venous Disease Background
    149. 2 Pathophysiology of Chronic Venous Insufficiency
    150. 3 Chronic Venous Disease Scoring
    151. 4 Natural History and Disease Progression
    152. 5 Patient Selection and Pre-procedure Evaluation for Sclerotherapy of Lower Limb Chronic Venous Disease
    153. 6 Special Populations for Sclerotherapy
    154. 7 Outcomes and Efficacy of Sclerotherapy for Chronic Venous Disease Treatment
    155. 8 Future Perspectives
    156. 10. Sclerotherapy by Saphenous Vein Catheters
    157. 1 Historical Evolution
    158. 2 The Rationale of Catheter-Directed Sclerotherapy
    159. 3 Patient Selection and Indications
    160. 4 Pre-procedural Evaluation
    161. 5 Catheter Systems and Equipment
    162. 6 Procedural Technique
    163. 7 Post-procedural Care and Follow-Up
    164. 8 Outcomes
    165. 11. Sclerotherapy for Lower Limb Telangiectasia Treatment
    166. 1 Background
    167. 2 Pathophysiology of Telangiectasias of the Lower Limbs
    168. 3 Principles of Aesthetic Sclerotherapy
    169. 4 Technical Notes
    170. 5 Complications Management
    171. 6 Future Perspectives
    172. 12. Cryo-Laser and Cryo-Sclerotherapy (CLaCS)
    173. 1 Introduction
    174. 2 CLaCS Rationale
    175. 3 Pertinent Anatomy and Pathophysiology
    176. 4 Patient Selection and Clinical Evaluation
    177. 5 Principles of Cryo-Laser Technology
    178. 6 Principles of Cryo-Sclerotherapy
    179. 7 Technical Notes
    180. 8 Safety Considerations and Complication Prevention
    181. 9 Clinical Outcomes and Evidence
    182. 10 Training and Learning Curve
    183. 13. Foam Sclerotherapy for Pelvic Venous Disorders Treatment
    184. 1 Prevalence and Quality of Life of Chronic Pelvic Pain
    185. 2 Nomenclature of Pelvic Venous Disorders
    186. 3 Pathophysiology
    187. 4 Clinical Work-Up
    188. 5 Instrumental Examination
    189. 6 Classification
    190. 7 Treatment
    191. 8 Combined Embolization (Coils+Sclerofoam)
    192. 9 Sclerofoam Alone
    193. 10 Sclerofoam for Extra-Pelvic Veins
    194. 11 Conclusions
    195. 14. Sclerotherapy for Vascular Malformations
    196. 1 Endovascular Therapy in General
    197. 2 Indication for the Intervention
    198. 3 Ethanol Sclerotherapy
    199. 4 Sclerotherapy in General with Other Agents
    200. 5 Embolotherapy
    201. 6 Foam Sclerotherapy
    202. 7 Ultrasound-Guided Sclerotherapy (UGS) with Foam Sclerosants
    203. 8 Fluoroscopic and Ultrasound-Guided Sclerotherapy (FUGS)
    204. 15. Tips and Tricks in Sclerotherapy
    205. 1 Strategic Indications and Case Selection
    206. 2 Pre-procedure Optimization
    207. 3 Choice of Sclerosant: Practical Nuances
    208. 4 Foam Sclerotherapy: Technical Pearls
    209. 5 Injection Techniques and Access Tips
    210. 6 Managing and Preventing Complications
    211. 7 Special Clinical Scenarios
    212. 8 Telangiectasias vs. Reticular Veins: Different Tactics
    213. 9 Post-procedure Follow-Up and Retreatment
    214. 10 Expert Tricks and Personal Practice Insights
    215. 11 Clinical Example
    216. 11.1 Foam Sclerotherapy of the Great Saphenous Vein Using a Standard Central Venous Catheter (Practical and Personal Tips and Tricks to Improve Clinical Outcomes)
    217. 11.1.1 Clinical Case and Iconography Provided by Rodrigo Rial
    218. 12 Discussion
    219. 16. Considerations on Medical Technological Advancement and Their Regulation
    220. 1 Introduction
    221. 2 Technological and Conceptual Evolution of Sclerotherapy
    222. 3 Regulatory Framework and Certification of Medical Technologies in Sclerotherapy
    223. 4 Validation, Standardization, and Reproducibility
    224. 5 Recent and Future of Pharmacological Research Applied to Microfoam
    225. 6 Conclusions
    226. 17. Similarities and Controversies in International Sclerotherapy Guidelines
    227. 1 Introduction
    228. 2 Historical Context
    229. 3 Similarities and Discrepancies
    230. 4 Absolute and Relative Contraindications
    231. 5 Methodological Underpinnings: Why Guideline Panels Disagree Even When Reading the Same Studies
    232. 6 National Clinical Governance Versus International Guidance in Sclerotherapy
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów